Translate Bio, Inc. (NASDAQ:TBIO) Director Owen Hughes sold 29,860 shares of the business’s stock in a transaction that occurred on Tuesday, September 14th. The stock was sold at an average price of $38.00, for a total transaction of $1,134,680.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of NASDAQ:TBIO opened at $37.36 on Wednesday. The stock has a 50-day simple moving average of $34.87 and a 200-day simple moving average of $25.36. The stock has a market capitalization of $2.82 billion, a P/E ratio of 66.71 and a beta of 0.99. Translate Bio, Inc. has a 1 year low of $11.91 and a 1 year high of $37.99.
Translate Bio (NASDAQ:TBIO) last issued its quarterly earnings data on Wednesday, August 4th. The company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.44. The firm had revenue of $72.65 million during the quarter, compared to the consensus estimate of $38.23 million. Translate Bio had a return on equity of 1.50% and a net margin of 17.97%. Research analysts expect that Translate Bio, Inc. will post -0.6 EPS for the current year.
Several analysts have weighed in on the stock. Roth Capital dropped their target price on shares of Translate Bio from $45.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 3rd. Zacks Investment Research upgraded shares of Translate Bio from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, August 4th. William Blair cut shares of Translate Bio from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 3rd. SVB Leerink lifted their price objective on shares of Translate Bio from $19.00 to $38.00 and gave the company a “market perform” rating in a research note on Tuesday, August 3rd. Finally, TheStreet upgraded shares of Translate Bio from a “d+” rating to a “c” rating in a research note on Thursday, May 27th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $27.13.
About Translate Bio
Translate Bio, Inc engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.